Figures computed from official regulatory filings — .
Analysttarget 65.48 USD (+179%) · consensus 4.67/5 · 11 buy · 1 hold · 0 sell
Ownershipinsiders 1.26% · institutions 97.94% · short 14.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for uniQure N.V. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
377 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Kapusta Matthew C | Sell | $408.8K | SEC |
| Kapusta Matthew C | Sell | $348.8K | SEC |
| Kapusta Matthew C | Exercise | $408.8K | SEC |
| Kapusta Matthew C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kapusta Matthew C | Sell | $194.5K | SEC |
| Kaye Jack | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Abi-Saab Walid | Exercise | $55.9K | SEC |
| Abi-Saab Walid | Sell | $464.6K | SEC |
| Kaye Jack | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kaye Jack | Exercise | $152K | SEC |
| Kaye Jack | Exercise | $344.3K | Unusual size | SEC |
| Abi-Saab Walid | Sell | $928K | Unusual size | SEC |
| Abi-Saab Walid | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kaye Jack | Sell | $190.9K | SEC |
| Kaye Jack | Sell | $792.1K | Unusual size | SEC |
| Abi-Saab Walid | Sell | $67.2K | SEC |
| Kapusta Matthew C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kapusta Matthew C | Sell | $334.8K | SEC |
| Kapusta Matthew C | Exercise | $910.6K | SEC |
| Kapusta Matthew C | Sell | $1.4M | SEC |
| Kapusta Matthew C | Exercise | $130.9K | SEC |
| Kapusta Matthew C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kapusta Matthew C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kapusta Matthew C | Sell | $1.9M | SEC |
| Kapusta Matthew C | Sell | $563.6K | SEC |